

Kevin J Harrington

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5274154/kevin-j-harrington-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

11,327
citations

41
h-index

106
g-index

152
ext. papers

14,845
ext. citations

9.4
avg, IF

6.07
L-index

#	Paper	IF	Citations
137	Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.. <i>BMC Medicine</i> , 2022 , 20, 16	11.4	1
136	Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. 2022 , 10,		6
135	Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102198	2.2	7
134	Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.. <i>Science Translational Medicine</i> , 2022 , 14, eabn2231	17.5	5
133	439 A phase 2 study of evorpcept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03 2021 , 9, A469-A469		
132	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	17
131	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study.. <i>Nature Cancer</i> , 2021 , 2, 1321-1337	15.4	24
130	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. <i>Nature Communications</i> , 2021 , 12, 1930	17.4	1
129	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 450-462	21.7	80
128	On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy 2021 , 9,		3
127	Tipifarnib in Head and Neck Squamous Cell Carcinoma With Mutations. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1856-1864	2.2	31
126	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. <i>Modern Pathology</i> , 2021 , 34, 532-541	9.8	19
125	The Changing Landscape of Therapeutic Cancer Vaccines- Novel Platforms and Neoantigen Identification. <i>Clinical Cancer Research</i> , 2021 , 27, 689-703	12.9	43
124	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.. <i>Nature Cancer</i> , 2021 , 2, 693-708	15.4	15
123	Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. <i>European Journal of Cancer</i> , 2021 , 153, 242-256	7.5	2
122	Inflammatory microenvironment remodelling by tumour cells after radiotherapy. <i>Nature Reviews Cancer</i> , 2020 , 20, 203-217	31.3	154
121	APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. <i>Nature Communications</i> , 2020 , 11, 790	17.4	25

120	Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States. <i>Journal of Medical Economics</i> , 2020 , 23, 442-447	2.4	5
119	Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. <i>European Journal of Cancer</i> , 2020 , 131, 9-15	7.5	14
118	Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score 2020 ,		5
117	Optimal acquisition scheme for flow-compensated intravoxel incoherent motion diffusion-weighted imaging in the abdomen: An accurate and precise clinically feasible protocol. <i>Magnetic Resonance in Medicine</i> , 2020 , 83, 1003-1015	4.4	6
116	Head and neck mucosal melanoma: The United Kingdom national guidelines. <i>European Journal of Cancer</i> , 2020 , 138, 11-18	7.5	18
115	Immunomodulatory activity of IR700-labelled affibody targeting HER2. <i>Cell Death and Disease</i> , 2020 , 11, 886	9.8	7
114	Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. <i>European Journal of Cancer</i> , 2020 , 136, 99-106	7.5	23
113	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective 2020 , 8,		5
112	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020 , 26, 5153-5161	12.9	23
111	Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer 2020 , 8,		4
110	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma 2019 , 7, 145		144
109	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1170-1180	13.4	20
108	Principal component analysis for fast and model-free denoising of multi b-value diffusion-weighted MR images. <i>Physics in Medicine and Biology</i> , 2019 , 64, 105015	3.8	12
107	Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. <i>Cancer Immunology Research</i> , 2019 , 7, 828-840	12.5	8
106	ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2019 , 25, 3392-3403	12.9	79
105	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) 2019 , 7, 184		223
104	Optimizing oncolytic virotherapy in cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2019 , 18, 689-706	64.1	198
103	Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21 2019 , 7, 164		17

102	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 1915-1928	4.0	839
101	Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6000-6000	2.2	88
100	Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6026-6026	2.2	0
99	An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2671-TPS2671	2.2	0
98	Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTIM.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9524-9524	2.2	2
97	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 393, 156-167	4.0	674
96	NUT Carcinoma of the Salivary Glands: Clinicopathologic and Molecular Analysis of 3 Cases and a Survey of NUT Expression in Salivary Gland Carcinomas. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 877-884	6.7	30
95	Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. <i>International Journal of Cancer</i> , 2018 , 142, 2363-2374	7.5	34
94	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	206
93	Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. <i>Gut</i> , 2018 , 67, 562-573	19.2	33
92	Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma 2018 ,		18
91	Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor) 2018 ,		5
90	Nivolumab (nivo) vs investigator choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6028-6028	2.2	7
89	Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6001-6001	2.2	16
88	Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6045-6045	2.2	6
87	A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS6090-TPS6090	2.2	8
86	Molecular prediction of lymph node metastases using immunohistochemical analysis of primary oral tongue squamous cell carcinomas.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 6054-6054	2.2	
85	Hope for salivary gland cancer (SGC): EORTC HNCGR/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (11CT01860570). <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS6088-TPS6088	2.2	

84	Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 2018 ,		3
83	Warthin Tumor-Like Mucoepidermoid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2018 , 26, 31-33	1.2	9
82	Dosimetric Implications of Computerised Tomography-Only versus Magnetic Resonance-Fusion Contouring in Stereotactic Body Radiotherapy for Prostate Cancer. <i>Medicines (Basel, Switzerland)</i> , 2018 , 5,	4.1	4
81	Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004). <i>European Journal of Cancer</i> , 2018 , 103, 249-258	7.5	7
80	APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. <i>Molecular Therapy - Oncolytics</i> , 2018 , 11, 1-13	6.4	6
79	Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates. <i>Cancer Drug Discovery and Development</i> , 2018 , 99-127	0.3	1
78	A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017 , 122, 207-211	5.3	20
77	Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 25-34	6.1	62
76	The emerging potential of magnetic resonance imaging in personalizing radiotherapy for head and neck cancer: an oncologist's perspective. <i>British Journal of Radiology</i> , 2017 , 90, 20160768	3.4	29
75	Subversion of NK-cell and TNF Immune Surveillance Drives Tumor Recurrence. <i>Cancer Immunology Research</i> , 2017 , 5, 1029-1045	12.5	15
74	A practical guide to the handling and administration of talimogene laherparepvec in Europe. <i>OncoTargets and Therapy</i> , 2017 , 10, 3867-3880	4.4	24
73	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1104-1115	21.7	232
72	Combining Molecularly Targeted Agents: Is More Always Better?. <i>Clinical Cancer Research</i> , 2017 , 23, 1123-1125	14.256	
71	Blood transfusion during radical chemo-radiotherapy does not reduce tumour hypoxia in squamous cell cancer of the head and neck. <i>British Journal of Cancer</i> , 2017 , 116, 28-35	8.7	16
70	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2017 , 7, 72	5.3	86
69	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6050-6050	2.2	6
68	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5-5	2.2	1
67	Predicting response to radical (chemo)radiotherapy (R-CRT) with circulating HPV DNA and tumor DNA (ctDNA) analysis in locally-advanced head and neck squamous cell carcinoma (LAHNC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6043-6043	2.2	

66	Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A) 2017 ,		6
65	Contrast enhancement of carotid adventitial vasa vasorum as a biomarker of radiation-induced atherosclerosis. <i>Radiotherapy and Oncology</i> , 2016 , 120, 63-8	5.3	6
64	CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2042-54	6.1	31
63	Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis. <i>Radiotherapy and Oncology</i> , 2016 , 118, 323-9	5.3	15
62	Plaque Neovascularization Is Increased in Human Carotid Atherosclerosis Related to Prior Neck Radiotherapy: A Contrast-Enhanced Ultrasound Study. <i>JACC: Cardiovascular Imaging</i> , 2016 , 9, 668-75	8.4	9
61	Reply to N.F. Saba and S.J. Wong. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2073-4	2.2	
60	Acoustic parameters of speech: Lack of correlation with perceptual and questionnaire-based speech evaluation in patients with oral and oropharyngeal cancer treated with primary surgery. <i>Head and Neck</i> , 2016 , 38, 670-6	4.2	7
59	Arterial Stiffness as a Biomarker of Radiation-Induced Carotid Atherosclerosis. <i>Angiology</i> , 2016 , 67, 266-71	7.1	15
58	Contrast-enhanced ultrasound to assess plaque neovascularization in irradiated carotid arteries. <i>International Journal of Cardiology</i> , 2016 , 202, 3-4	3.2	3
57	First results of COSTAR: A randomised trial of 3-dimensional conformal radiotherapy (3DCRT) vs cochlea-sparing intensity modulated radiotherapy (CS-IMRT) in patients with parotid cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6006-6006	2.2	1
56	Further evaluations of nivolumab (nivo) versus investigator choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 6009-6009	2.2	27
55	Phase I/II canon study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16016-e16016	2.2	5
54	PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2103-TPS2603	2.2	2
53	Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3108-TPS3108	2.2	3
52	Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS6104-TPS6104	2.2	1
51	ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS6108-TPS6108	2.2	2
50	Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis. <i>Oncotarget</i> , 2016 , 7, 81208-81222	3.3	16
49	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. <i>OncoTargets and Therapy</i> , 2016 , 9, 7081-7093	4.4	69

48	The MRI-Linear Accelerator Consortium: Evidence-Based Clinical Introduction of an Innovation in Radiation Oncology Connecting Researchers, Methodology, Data Collection, Quality Assurance, and Technical Development. <i>Frontiers in Oncology</i> , 2016 , 6, 215	5.3	68
47	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2016 , 375, 1856-1867	59.2	2647
46	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. <i>Head and Neck</i> , 2016 , 38, 1752-1758	4.2	40
45	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. <i>Nature Reviews Cancer</i> , 2015 , 15, 409-25	31.3	1022
44	Attenuation Correction and Normalisation for Quantification of Contrast Enhancement in Ultrasound Images of Carotid Arteries. <i>Ultrasound in Medicine and Biology</i> , 2015 , 41, 1876-83	3.5	10
43	Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 1305-12	12.9	32
42	Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 507-15	4	26
41	Human Papillomavirus-Negative Pharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3251-61	2.2	40
40	69. Combination Therapy of Reovirus and PD-1 Blockade Effectively Establishes Tumor Control Via Innate and Adaptive Immune Responses. <i>Molecular Therapy</i> , 2015 , 23, S30	11.7	2
39	Comparison of CT number calibration techniques for CBCT-based dose calculation. <i>Strahlentherapie Und Onkologie</i> , 2015 , 191, 970-8	4.3	46
38	Phase I/II storm study: Intravenous delivery of a novel oncolytic immunotherapy agent, Cocksackievirus A21, in advanced cancer patients 2015 , 3, P341		4
37	Brain-sparing methods for IMRT of head and neck cancer. <i>PLoS ONE</i> , 2015 , 10, e0120141	3.7	11
36	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. <i>Molecular Therapy</i> , 2015 , 23, 931-942	11.7	29
35	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2780-8	2.2	1480
34	Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. <i>Molecular Therapy</i> , 2015 , 23, 845-856	11.7	9
33	Abstract CT205: Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients 2015 ,		2
32	KEYNOTE-040: A phase III randomized trial of pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS6084-TPS6084	2.2	15
31	Radiation-induced carotid artery atherosclerosis. <i>Radiotherapy and Oncology</i> , 2014 , 110, 31-8	5.3	75

30	The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. <i>Molecular Therapy</i> , 2014 , 22, 1936-48	11.7	14
29	Multiple cervical lymph node involvement and extra-capsular extension predict for contralateral nodal recurrence after ipsilateral radiotherapy for squamous cell carcinoma of the tonsil. <i>Oral Oncology</i> , 2014 , 50, 901-6	4.4	30
28	Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers. <i>Oral Oncology</i> , 2014 , 50, 1089-97	4.4	16
27	Treatment-related dysgeusia in head and neck cancer patients. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1106-17	4.7	44
26	Applications of coxsackievirus A21 in oncology. <i>Oncolytic Virotherapy</i> , 2014 , 3, 47-55	6	51
25	A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5009-22	12.9	94
24	Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. <i>Molecular Therapy</i> , 2014 , 22, 1851-63	11.7	45
23	Oncolytic wild-type reovirus infection in brain tumors following intravenous administration in patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3104-3104	2.2	1
22	Final analysis: A randomized, blinded, placebo (P)-controlled phase III study of adjuvant postoperative lapatinib (L) with concurrent chemotherapy and radiation therapy (CH-RT) in high-risk patients with squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 6005-6005	2.2	16
21	Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. <i>Nature Medicine</i> , 2013 , 19, 1625-1631	50.5	41
20	Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. <i>European Journal of Cancer</i> , 2013 , 49, 1609-18	7.5	88
19	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2013 , 49, 2512-21	7.5	11
18	Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. <i>Molecular Therapy</i> , 2013 , 21, 1507-16	11.7	29
17	Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. <i>Science Translational Medicine</i> , 2012 , 4, 138ra77	17.5	112
16	Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. <i>Radiotherapy and Oncology</i> , 2012 , 103, 82-7	5.3	45
15	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. <i>BMC Cancer</i> , 2012 , 12, 368	4.8	42
14	Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. <i>Nature Biotechnology</i> , 2012 , 30, 337-43	44.5	85
13	Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. <i>Clinical Cancer Research</i> , 2012 , 18, 2080-9	12.9	131

12	Phase II trial of intravenous administration of Reolysin(□) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. <i>Molecular Therapy</i> , 2012 , 20, 1998-2003	11.7	110
11	Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. <i>Nature Medicine</i> , 2011 , 17, 854-9	50.5	74
10	Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. <i>BMC Cancer</i> , 2011 , 11, 221	4.8	44
9	Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. <i>Molecular Therapy</i> , 2011 , 19, 140-9	11.7	29
8	A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 581-8	12.9	88
7	Using a Bayesian Feature-selection Algorithm to Identify Dose-response Models Based on the Shape of the 3D Dose-distribution: An Example from a Head-and-neck Cancer Trial 2010 ,		3
6	REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 5564-72	12.9	108
5	Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. <i>Clinical Cancer Research</i> , 2009 , 15, 561-9	12.9	56
4	Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. <i>Clinical Cancer Research</i> , 2009 , 15, 6158-66	12.9	75
3	Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. <i>Clinical Cancer Research</i> , 2008 , 14, 259-69	12.9	142
2	A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7127-37	12.9	177
1	MET and RON Receptor Tyrosine Kinases: Novel Therapeutic Targets in Squamous Cell Carcinoma of the Head and Neck. <i>Current Enzyme Inhibition</i> , 2007 , 3, 1-12	0.5	2